Johnson & Johnson has obtained US approval for the first protease inhibitor-containing single-tablet regimen for HIV, but Symtuza faces cloudy commercial prospects due to US treatment guidelines that prefer regimens anchored by integrase inhibitors and concerns about eventual generic availability of its components.
Symtuza, which combines J&J’s protease inhibitor darunavir (Prezista/Prezcobix) with three agents licensed from HIV leader Gilead Sciences Inc., was...